ClinicalTrials.gg
RecruitingNCT07280039MUSIC 2Updated Oct 19, 2026

Mortality and Muscle Mass Loss in Critically Ill Patients.

An observational study in Mortality and Muscle Loss, sponsored by Brno University Hospital. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Brno University Hospital · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 19, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
386
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to monitor changes in muscle mass in critically ill patients and to verify whether a decrease in muscle mass of ≥10% during the first 7 days of hospitalization is associated with increased 28-day mortality. We will be used ultrasound for measurement the rectus femoris cross sectional area.

Read the detailed description

All patients will be admitted to participating ICU centers from December 2025 to December 2026 will be screened and enrolled based on the inclusion and exclusion criteria. Informed consent will be requested. Ultrasound measurements will be performed by the same investigator within the first 24h after ICU admission and again on day 7 of the patient´s ICU stay. All patient data will be entered into case report form by a study physician. In the follow-up will be determined 28 mortality.

02

Conditions studied

  • Mortality
  • Muscle Loss

Keywords

  • Mortality
  • Muscle loss
  • Muscle ultrasound
  • Critically ill
  • Rectus femoris cross area
03

In context

Muscular Atrophy

412 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.

This study's planned enrollment of 386 is above the median of 61 across 73 observational studies indexed under Muscular Atrophy.

Browse Muscular Atrophy studies →

Lead sponsor

Brno University Hospital is the lead sponsor of 91 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically ill adult patients will be admitted to intensive care unit with suspect length of artificial ventilation more than 48 hours.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥18 years
  • mechanical ventilation expected for at least 48 hours

Exclusion criteria

Exclusion Criteria:

  • Clinical Frailty Score above 7 prior admission
  • Neuromuscular disease in previous medical history
  • Amputated lower extremities
  • Trauma of lower extremities involving tights
  • Conditions affecting the nervous system with involvement of the thigh muscle
  • Inability to cooperate during ultrasound examination
  • Inability to perform ultrasound examination on day 7

    9. Inability to perform ultrasound examination on day 7

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
386 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Relationship between muscle loss and 28 day mortality

    Critically ill patients with a ≥10% decrease in rectus femoris cross-sectional area have increased 28 day mortality.

    Time frame: 28 days after enrollment

Secondary outcomes

  1. Incidence of a significant decrease in rectus femoris cross-sectional area

    A decrease in rectus femoris cross-sectional area of 10% or more measured by ultrasound.

    Time frame: first 7 days of ICU stay

  2. Incidence of an insignificant decrease in rectus femoris cross-sectional area

    A decrease in rectus femoris cross-sectional area of less than 10% measured by ultrasound.

    Time frame: first 7 days ICU stay

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
The University Hospital Brno is now Recruiting
Oct 19, 2026
Start date
Dec 15, 2025→Mar 27, 2026 (actual)
Oct 19, 2026
Primary completion
Dec 15, 2025→Dec 15, 2027
Oct 19, 2026
Study completion
Dec 15, 2026→Jan 15, 2028
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    The University Hospital Brno is now Recruiting
    Start date Dec 15, 2025→Mar 27, 2026 (now actual)
    Primary completion Dec 15, 2025→Dec 15, 2027
    Study completion Dec 15, 2026→Jan 15, 2028
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07280039
Lead sponsor
Brno University Hospital
Responsible party
Roman Gal (head of the department, Brno University Hospital) — Principal investigator
First posted
Dec 12, 2025
Start date
Mar 27, 2026
Primary completion
Dec 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Jana Fialová, M.D.
Contact
1149@fnbrno.cz
+42053322305
Roman Gal, M.D., PhD
study chair · Brno University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion